← Back to Clinical Trials
Recruiting Phase 4 NCT05783661

NCT05783661 Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05783661
Status Recruiting
Phase Phase 4
Sponsor Eva Bonfill
Condition Decompensated Cirrhosis
Study Type INTERVENTIONAL
Enrollment 198 participants
Start Date 2023-12-11
Primary Completion 2026-08

Trial Parameters

Condition Decompensated Cirrhosis
Sponsor Eva Bonfill
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 198
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-12-11
Completion 2026-08
Interventions
Conventional antibiotic strategiesRegimens guided by epidemiological surveillance

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Study to comparing conventrional antibiotic strategies versus regimens guided by epidemiological surveillance in infected patients with cirrhosis.

Eligibility Criteria

Inclusion Criteria: 1. Cirrhotic patients with acute decompensation aged ≥18 years. 2. Proven or suspected bacterial infection requiring antibiotic therapy (diagnosis will be established according to local guidelines, Appendix 1). 3. Signed informed consent or consent given by their legal representatives or close relatives. Exclusion Criteria: 1. Bacterial infection lasting for \> 48 hours. 2. Infection in a critically ill cirrhotic patient (ICU admission). In this population, epidemiological surveillance is standard clinical practice. 3. Evidence of current locally advanced or metastatic malignancy (patients with hepatocellular carcinoma within the Milan criteria and non-melanocytic skin cancer can be included). 4. Pregnant and/or breast-feeding woman. 5. Patients who cannot provide prior informed consent and when there is documented evidence that the patient has no legal surrogate decision-maker and it appears unlikely that the patient will regain consciousness or sufficient ability

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology